8 Aug 2012 14:57
|
Futura Medical plc
("Futura" or "the Company")
CSD500 UPDATE
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, confirms that it is in negotiations with Reckitt Benckiser regarding the parties' options in relation to the global licence agreement for CSD500.
The outcome of these negotiations is uncertain. Futura expects to update the market shortly.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive
| Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com | www.futuramedical.com |
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
For media enquiries please contact: |
|
|
|
Buchanan |
|
Mark Court / Fiona Henson / Sophie Cowles | Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Futura Medical (FUM)